The ascension of copyright’s drug initially fueled significant progress in the medicinal sector, producing a understanding of easy profits. However, funding in companies solely reliant on blockbuster drugs like Viagra presents considerable risks. Intellectual property end has led generic challeng

The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and substantial returns i